Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Piotr A. Klimiuk"'
Autor:
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA).
Externí odkaz:
https://doaj.org/article/6b49e98734e7429687859127a57bc3fa
Autor:
Edward Keystone, Josef S Smolen, Gerd R Burmester, Slawomir Jeka, Pawel Hrycaj, Janusz Jaworski, Anna Dudek, Artur Racewicz, Agnieszka Zielinska, YunJu Bae, Rafal Wojciechowski, Marek Krogulec, Jakub Trefler, Katarzyna Kolossa, Magdalena Krajewska-Włodarczyk, Piotr Adrian Klimiuk, SungHyun Kim, GoEun Yang, YooBin Jung, JiWoo Hong
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Objectives To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA).Methods This double-blind, phase III study randomised (1:1) patients to receive CT-P47 or r-TCZ (8 mg/kg
Externí odkaz:
https://doaj.org/article/57062166f2dd4fe39a65b97114a32a54
Publikováno v:
Rheumatology, Vol 48, Iss 6, Pp 416-420 (2010)
Stężenie i mikroheterogenność białek ostrej fazy (BOF) ulegazmianom w ostrych i przewlekłych stanach zapalnych. Zmianyjakościowe niektórych białek ostrej fazy są określane jako mikroheterogennośćgłówna. Elektroforeza dwóch kierunków
Externí odkaz:
https://doaj.org/article/375149519a9f4cacb6b0ba716ebb3594
Autor:
Sung Hyun Kim, Go Eun Yang, Marek Krogulec, Janusz Jaworski, Sang Joon Lee, Jonathan Kay, Anna Dudek, Edward C. Keystone, Yun Ju Bae, Jae Kyoung Yoo, Piotr Adrian Klimiuk, Piotr Wiland, Rafał Wojciechowski, Daniel E. Furst, Sławomir Jeka, Magdalena Krajewska-Włodarczyk, Jakub Trefler, Agnieszka Zielińska, Katarzyna Bartnicka-Maslowska
Publikováno v:
Rheumatology (Oxford, England). 61(4)
Objective To compare the safety and efficacy of switching from reference adalimumab to adalimumab biosimilar CT-P17 with continuing reference adalimumab/CT-P17 in active RA. Methods This double-blind, phase III study randomized (1:1) subjects with ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc903606c0634f5a88282630baf45975
https://pubmed.ncbi.nlm.nih.gov/34559204
https://pubmed.ncbi.nlm.nih.gov/34559204
Autor:
Katarzyna Bartnicka-Maslowska, Jae Kyoung Yoo, Piotr Wiland, Magdalena Krajewska-Włodarczyk, Jakub Trefler, Yun Ju Bae, Jonathan Kay, Agnieszka Zielińska, Go Eun Yang, Janusz Jaworski, Sławomir Jeka, Daniel E. Furst, Rafał Wojciechowski, Sang Joon Lee, Anna Dudek, Marek Krogulec, Edward C. Keystone, Piotr Adrian Klimiuk
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA). Methods T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cabcce7cfdd984768e84738fd71a94c
https://doi.org/10.1186/s13075-020-02394-7
https://doi.org/10.1186/s13075-020-02394-7
Autor:
Sławomir Jeka, J. Trefler, Anna Dudek, Jonathan Kay, K. Bartnicka-Masłowska, R. Wojciechowski, Daniel E. Furst, Y. Bae, S. J. Lee, S. H. Kim, Magdalena Krajewska-Włodarczyk, J. Yoo, Agnieszka Zielińska, Piotr Wiland, E.C. Keystone, M. Krogulec, T. Kim, Janusz Jaworski, G. Yang, Piotr Adrian Klimiuk
Publikováno v:
Annals of the Rheumatic Diseases. 80:1123-1124
Background:Therapeutic equivalence of CT-P17 to reference adalimumab (ref-adalimumab) has been shown in patients with moderate-to-severe active rheumatoid arthritis (RA) through primary 24-week results [1]. Here, efficacy, pharmacokinetics (PK), safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b019fb3cbf69fb37504c1e2a5b37ddb
https://doi.org/10.1136/annrheumdis-2021-eular.325
https://doi.org/10.1136/annrheumdis-2021-eular.325
Publikováno v:
Reumatologia
Rheumatology, Vol 55, Iss 2, Pp 73-78 (2017)
Rheumatology, Vol 55, Iss 2, Pp 73-78 (2017)
Objectives: Rheumatic diseases such as osteoarthritis and rheumatoid arthritis constitute the most frequent pathological states leading to the development of foot deformities, which reduce quality of life and cause disability. The aim of the present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b2e830d8c46176641b1dd45d44d2b05
https://doi.org/10.5114/reum.2017.67601
https://doi.org/10.5114/reum.2017.67601
Publikováno v:
Expert opinion on biological therapy. 19(10)
Objective: To evaluate long-term safety, efficacy, and immunogenicity of BI 695501 in patients with moderately-to-severely active rheumatoid arthritis (RA) who have completed VOLTAIRE-RA. Methods: Eligible patients for this phase 3b open-label extens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::334bb766959d9d29193d3d475fb0018e
https://pubmed.ncbi.nlm.nih.gov/31387417
https://pubmed.ncbi.nlm.nih.gov/31387417
Autor:
Piotr Adrian Klimiuk, Halina Gabryel-Porowska, Ewa Gińdzieńska-Sieśkiewicz, Joanna Rojewska, Stanisław Sierakowski, Izabela Domysławska, Agnieszka Sulik, Iwona Radziejewska
Publikováno v:
Advances in Medical Sciences. 61:193-197
In patients with active rheumatoid arthritis (RA) decrease of galactosylation is correlated with disease activity. The aim of our study was to evaluate an effect of methotrexate therapy on glycosylation disturbances of IgG in RA patients.IgG glycosyl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa77a7759ed42611717077b900de818
https://doi.org/10.1016/j.advms.2015.12.009
https://doi.org/10.1016/j.advms.2015.12.009
Publikováno v:
Expert opinion on drug delivery. 15(6)
This study examined the patient handling experience and self-injection success of patients with rheumatoid arthritis (RA) administering BI 695501 using an AI.This Phase II, 7-week, open-label, interventional study (NCT02636907) included adult patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52afadeedea56f13eacdad68bef7c893
https://pubmed.ncbi.nlm.nih.gov/29764238
https://pubmed.ncbi.nlm.nih.gov/29764238